Recent Finacing
Recent Raise
Alveron Pharma develops OKL-1111, a rapid IV synthetic agent that binds a downstream clotting factor to reverse anticoagulants and platelet inhibitors and limit hematoma expansion in intracranial hemorrhage.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Alveron Pharma.
